Kanada - Inggeris - Health Canada

teva canada limited - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 75mg - dabigatran etexilate (dabigatran etexilate mesilate) 75mg - direct thrombin inhibitors

Kanada - Inggeris - Health Canada

teva canada limited - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 150mg - dabigatran etexilate (dabigatran etexilate mesilate) 150mg - direct thrombin inhibitors

Kanada - Inggeris - Health Canada

apotex inc - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 75mg - dabigatran etexilate (dabigatran etexilate mesilate) 75mg - direct thrombin inhibitors

Kanada - Inggeris - Health Canada

apotex inc - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 110mg - dabigatran etexilate (dabigatran etexilate mesilate) 110mg - direct thrombin inhibitors

Kanada - Inggeris - Health Canada

apotex inc - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 150mg - dabigatran etexilate (dabigatran etexilate mesilate) 150mg - direct thrombin inhibitors

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 172.95 mg (equivalent: dabigatran etexilate, qty 150 mg) - capsule, hard - excipient ingredients: dimeticone 350; purified talc; hyprolose; purified water; indigo carmine; hypromellose; carrageenan; acacia; potassium chloride; titanium dioxide; tartaric acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 126.83 mg (equivalent: dabigatran etexilate, qty 110 mg) - capsule, hard - excipient ingredients: hyprolose; hypromellose; tartaric acid; dimeticone 350; potassium chloride; acacia; purified talc; titanium dioxide; carrageenan; indigo carmine; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 86.48 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: hypromellose; titanium dioxide; potassium chloride; purified talc; carrageenan; tartaric acid; hyprolose; purified water; acacia; dimeticone 350; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: purified water; hypromellose phthalate; tartaric acid; butylated hydroxytoluene; hyprolose; microcrystalline cellulose; dichloromethane; purified talc; isopropyl alcohol; macrogol 600; citric acid monohydrate; ethanol; povidone; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; macrogol 8000; hypromellose; sunset yellow fcf - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: purified water; hypromellose phthalate; hyprolose; dichloromethane; tartaric acid; ethanol; butylated hydroxytoluene; povidone; purified talc; citric acid monohydrate; isopropyl alcohol; microcrystalline cellulose; macrogol 600; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; hypromellose; sunset yellow fcf; macrogol 8000 - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.